Novo Nordisk Looks To Broaden Therapeutic Reach With Move Into ATTR
Company Acquires Phase II-Ready Prothena Drug
The deal leaves PRX004 in the capable hands of Novo Nordisk, which is hoping to expand beyond obesity and diabetes, while Prothena can focus on the rest of its pipeline.
